CLINICAL TRIAL / NCT05783622

Inclusion Criteria: - Subjects ≥18 years of age at the time of signing informed consent - Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, RCC, SCLC, PDAC, TNBC - Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type - Adequate organ function - At least 1 measurable lesion per RECIST 1.1 Exclusion Criteria: - Treatment with anti-cancer therapy within 28 days or ≤5 elimination half-lives, whichever is earlier, before enrollment - Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy - Prior treatment with CD3 engaging bispecific antibodies - Clinically significant cardiovascular diseases - Active clinically significant infection (bacterial, viral, fungal, mycobacteria, or other) - On supplemental oxygen - Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment